NASDAQ: DNTHDianthus Therapeutics Inc Stock
$94.34+4.13 (+4.58%)
Updated Jul 2, 2026
DNTH Price
$94.34
Fair Value Price
-$3.06
Market Cap
$5.16B
52 Week Low
$17.88
52 Week High
$98.64
P/E
-22.36x
P/B
4.29x
P/S
3,017.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.34M
Earnings
-$173.66M
Gross Margin
100%
Operating Margin
-12,998.5%
Profit Margin
-12,998.5%
Debt to Equity
0.04
Operating Cash Flow
-$130M
Beta
1.02
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
DNTH Overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DNTH's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DNTH
Ranked#154 of 463
Ranked#154 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important DNTH news, forecast changes, insider trades & much more!
DNTH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DNTH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DNTH ($94.34) is overvalued by 3,185.83% relative to our estimate of its Fair Value price of -$3.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
DNTH ($94.34) is not significantly undervalued (3,185.83%) relative to our estimate of its Fair Value price of -$3.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
DNTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more DNTH due diligence checks available for Premium users.
Valuation
DNTH fair value
Fair Value of DNTH stock based on Discounted Cash Flow (DCF)
Price
$94.34
Fair Value
-$3.06
Undervalued by
3,185.83%
DNTH ($94.34) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
DNTH ($94.34) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
DNTH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DNTH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-22.36x
Industry
17.59x
Market
8.54x
DNTH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.29x
Industry
5.6x
DNTH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DNTH's financial health
Profit margin
Revenue
$463.0k
Net Income
-$40.8M
Profit Margin
-8,819.4%
DNTH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
DNTH's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.2B
Liabilities
$45.6M
Debt to equity
0.04
DNTH's short-term assets ($1.12B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DNTH's short-term assets ($1.12B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DNTH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DNTH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$28.9M
Investing
-$134.0M
Financing
$739.4M
DNTH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DNTH vs Biotech Stocks
Dianthus Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.